Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Shanghai MicroPort Endovascular MedTech (Group) Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 15.82%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SHSE:688016's 3-Year ROIIC % is ranked better than 66.42% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 1.57
vs SHSE:688016: 15.82
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Shanghai MicroPort Endovascular MedTech (Group) Co 3-Year ROIIC % Related Terms
Shanghai MicroPort Endovascular MedTech (Group) Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort Endovascular MedTech (Group) Co 3-Year ROIIC % Chart
Shanghai MicroPort Endovascular MedTech (Group) Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai MicroPort Endovascular MedTech (Group) Co 3-Year ROIIC % vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) has a 3-Year ROIIC % of 15.82 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. This is 58% below median its historical median of 37.26. Over the past decade, Shanghai MicroPort Endovascular MedTech (Group) Co's 3-Year ROIIC % has ranged from 9.05 to 196.11. According to the industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #267 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 33.6%.
Is Shanghai MicroPort Endovascular MedTech (Group) Co's 3-Year ROIIC % too high?
Shanghai MicroPort Endovascular MedTech (Group) Co's current 3-Year ROIIC % of 15.82 is 58% below median its 10-year median of 37.26. Over the past 10 years, this metric has ranged from a low of 9.05 to a high of 196.11. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.57. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 15.82 is 907.6% above this industry median. Based on the distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #267 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Shanghai MicroPort Endovascular MedTech (Group) Co has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort Endovascular MedTech (Group) Co's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #267 out of 795 companies for 3-Year ROIIC %. This puts Shanghai MicroPort Endovascular MedTech (Group) Co in the upper half of its industry. The industry median 3-Year ROIIC % is 1.57. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 15.82 is 907.6% above this benchmark. Historically, Shanghai MicroPort Endovascular MedTech (Group) Co's own 3-Year ROIIC % has ranged from 9.05 to 196.11 over the past decade. While the company's 10-year median is 37.26 vs. the industry median of 1.57, Shanghai MicroPort Endovascular MedTech (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.57, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai MicroPort Endovascular MedTech (Group) Co's current 3-Year ROIIC % of 15.82 is 907.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort Endovascular MedTech (Group) Co's current 3-Year ROIIC % is 15.82, which is 58% below median its own 10-year median of 37.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort Endovascular MedTech (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥122.12, compared to a current price of ¥91.69 — trading 24.9% below its estimated fair value. The current 3-Year ROIIC % is 15.82, which is 58% below median its 10-year median of 37.26 and 907.6% above the Medical Devices & Instruments industry median of 1.57. Shanghai MicroPort Endovascular MedTech (Group) Co's overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016), the current 3-Year ROIIC % is 15.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co stock appears to be undervalued.
The current stock price of ¥91.69 is trading 24.9% below its estimated GF Value™ of ¥122.12.
GuruFocus considers Shanghai MicroPort Endovascular MedTech (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688016:
3-Year ROIIC %: 15.82 (58% below median its 10-year median of 37.26)
GF Value™: ¥122.12 vs. price of ¥91.69 (24.9% below fair value)
Industry Position: 907.6% above the Medical Devices & Instruments median (#267 of 795)
No single metric tells the full story. See the SHSE:688016 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Microport Endovascular Medtech Co Ltd is engaged in the Research, development, production and sales of interventional medical devices for the aorta and peripheral blood vessels.
99GF Score
Get the complete analysis for SHSE:688016
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688016 has been successfully added to your 
